STU:640'
s Pretax Margin % Range Over the Past 10 Years
Min: 3.25 Med: 4.14 Max: 5.13
Current: 4.37
STU:640's Pretax Margin % is ranked worse than 56.71% of 954
companies
in the Drug Manufacturers industry
Industry Median: 7.295
vs STU:640: 4.37
China Resources Pharmaceutical Group (STU:640) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
China Resources Pharmaceutical Group Pretax Margin % Related Terms
China Resources Pharmaceutical Group Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Pharmaceutical Group Pretax Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Pharmaceutical Group's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Pharmaceutical Group Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Resources Pharmaceutical Group's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where China Resources Pharmaceutical Group's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Pharmaceutical Group (STU:640) has a Pretax Margin % of 3.91% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on China Resources Pharmaceutical Group and its competitors. This is near median its historical median of 4.14. Over the past decade, China Resources Pharmaceutical Group's Pretax Margin % has ranged from 3.25 to 5.13. According to the industry distribution chart, China Resources Pharmaceutical Group ranks #541 out of 954 companies in the Drug Manufacturers industry, placing it in the top 56.7%.
Is China Resources Pharmaceutical Group's Pretax Margin % too high?
China Resources Pharmaceutical Group's current Pretax Margin % of 3.91% is near median its 10-year median of 4.14. Over the past 10 years, this metric has ranged from a low of 3.25 to a high of 5.13. The Drug Manufacturers industry median Pretax Margin % is 7.30. China Resources Pharmaceutical Group's value of 3.91% is 46.4% below this industry median. Based on the distribution chart, China Resources Pharmaceutical Group ranks #541 out of 954 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, China Resources Pharmaceutical Group has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Pharmaceutical Group's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, China Resources Pharmaceutical Group ranks #541 out of 954 companies for Pretax Margin %. This places China Resources Pharmaceutical Group in the lower half of its industry. The industry median Pretax Margin % is 7.30. China Resources Pharmaceutical Group's value of 3.91% is 46.4% below this benchmark. Historically, China Resources Pharmaceutical Group's own Pretax Margin % has ranged from 3.25 to 5.13 over the past decade. While the company's 10-year median is 4.14 vs. the industry median of 7.30, China Resources Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Pharmaceutical Group's current Pretax Margin % of 3.91% is 46.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on China Resources Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Pharmaceutical Group's current Pretax Margin % is 3.91%, which is near median its own 10-year median of 4.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group (STU:640) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.64, compared to a current price of €0.49 — trading 24.1% below its estimated fair value. The current Pretax Margin % is 3.91%, which is near median its 10-year median of 4.14 and 46.4% below the Drug Manufacturers industry median of 7.30. China Resources Pharmaceutical Group's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For China Resources Pharmaceutical Group (STU:640), the current Pretax Margin % is 3.91% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Pharmaceutical Group (STU:640) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group stock appears to be undervalued.
The current stock price of €0.49 is trading 24.1% below its estimated GF Value™ of €0.64.
GuruFocus considers China Resources Pharmaceutical Group to be Modestly Undervalued.
Key valuation signals for STU:640:
Pretax Margin %: 3.91% (near median its 10-year median of 4.14)
GF Value™: €0.64 vs. price of €0.49 (24.1% below fair value)
Industry Position: 46.4% below the Drug Manufacturers median (#541 of 954)
No single metric tells the full story. See the STU:640 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Pharmaceutical Group Business Description
China Resources Pharmaceutical Group Ltd is principally engaged in the manufacture, distribution and retail of pharmaceutical and healthcare products. Specifically, the Group has four reportable segments as follows: Pharmaceutical manufacturing business, Pharmaceutical distribution business, Pharmaceutical retail business , and Other business operations. The company generates majority of its revenue from the Pharmaceutical distribution business.
63GF Score
Get the complete analysis for STU:640
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:640 has been successfully added to your 
